Karnataka Bank. Rating: BUY. Bank - Private. Short Note. Brief Financials

Similar documents
Karnataka Bank Ltd. Rating: Buy. Bank- Private KBL STOCK IDEA

IDFC Ltd. Rating: BUY BFSI. IDFC Ltd STOCK IDEA

Investment Horizon: Though the ideal investment horizon for such ideas remain 6-9 months, our picks may provide some profit-making

City Union Bank BUY. 24 February 2016 INR82

HDFC Bank. BUY CMP (Rs.) 1,807 Target (Rs.) 2,000 Potential Upside 11%

L&T Infotech Limited

Federal Bank Ltd. Banking/Finance. Accumulate RETAIL EQUITY RESEARCH

Investment Horizon: Though the ideal investment horizon for such ideas remain 6-9 months, our picks may provide some profit-making

State Bank of India (SBI)

Salzer Electronics Ltd. Rating: Buy. Electrical Equipment SEL STOCK IDEA

HDFC Bank BUY. Performance Highlights. CMP `1,965 Target Price `2,350. Q2FY2019 Result Update Banking. 3-year price chart. Exhibit 1: Key Financials

Federal Bank BUY RETAIL EQUITY RESEARCH

Change EPS. (Rs) FY

SUBSCRIBE. Aavas Financiers ltd. Sector: HFC /Mid -Cap Note on IPO 19 September Objects of the Offer. Key Positives. Risks

ICICI Bank Banking BUY RETAIL EQUITY RESEARCH

HDFC Bank BUY. Performance Highlights. CMP `2,145 Target Price `2,500. Q3FY2019 Result Update Banking. 3-year price chart. Key financials (Standalone)

BUY. ICICI Bank RETAIL EQUITY RESEARCH. Banking. ddd******* GEOJIT Research. Strong traction in retail segment continues

Can Fin Homes BUY. 23 September 2015 INR821

Federal Bank BUY. Performance Highlights. Target Price. 1QFY2018 Result Update Banking. Stock Info Sector

State Bank of India (SBI) Banking. BUY Rating as per Large Cap 12 month investment period RETAIL EQUITY RESEARCH

ICICI Bank BUY. Performance Highlights. CMP Target Price `343 `460. Q3FY2019 Result Update Banking. 3-year price chart. Exhibit 1: Key Financials

ICICI BANK Ltd. BUY CMP (Rs.) 334 Target (Rs.) 382 Potential Upside 15% Tide set to turn favourably... For private circulation only

ICICI Bank BUY. Performance Highlights. CMP Target Price `328 `416. 3QFY2018 Result Update Banking. 3-year price chart. Key financials (Standalone)

RBL Bank Ltd. Banking. ACCUMULATE Rating as per Mid Cap 12 months investment period RETAIL EQUITY RESEARCH

HDFC Bank BUY. Operating performance strong; improved NIM. CMP `2,268 Target Price `2,500. Q4FY2019 Result Update Banking. 3-year price chart

Ujjivan Financial Services Ltd Banking/Finance BUY RETAIL EQUITY RESEARCH

Hold Target Price: Rs 574

Manappuram Finance (MGFL IN) Healthy operating performance

Axis Bank BUY. CMP Target Price `620 `750. Update Bank. Earnings to normalize with stabilizing credit costs. 3-year price chart.

Axis Bank Ltd. For private circulation only. Volume No.. III Issue No October 08, 2018

Capital First Ltd. NBFC. Buy RETAIL EQUITY RESEARCH

Agrochemicals. 3QFY18E Results Preview 09 JAN Basanth Patil

BUY. State Bank of India (SBI) Banking RETAIL EQUITY RESEARCH. Outlook getting better. CMP Rs278 TARGET Rs310 RETURN 12% 17 th November 2016

Reduce. Punjab National Bank Banking RETAIL EQUITY RESEARCH. Not out of the woods. GEOJIT BNP PARIBAS Research. 10 th August 2016 Q1FY17 RESULT UPDATE

FY17 FY18 FY19E FY20E

Punjab National Bank

ICICI Bank BUY. Performance Highlights. CMP Target Price `307 `411. 1QFY2019 Result Update Banking. 3-year price chart. Key financials (Standalone)

Manappuram Finance (MGFL IN) Growth picks up in gold loan; Microfinance drive profitability

Ujjivan Financial Services Ltd Banking/Finance. Accumulate RETAIL EQUITY RESEARCH

Ujjivan Financial Services Ltd.: Q3FY18 Result Update

BUY. State Bank of India (SBI) Banking RETAIL EQUITY RESEARCH. GEOJIT BNP PARIBAS Research. CMP Rs259 TARGET Rs284 RETURN 10% 22 nd August 2016

HDFC Bank Banking BUY RETAIL EQUITY RESEARCH

Quess Corp Limited. Wealth Management

HOLD. Buyback of Old Mutual s stake in K-Life KOTAK MAHINDRA BANK. Target Price: Rs 965

FY17 FY18 FY19E FY20E

BUY. Structural changes in the making CAPITAL FIRST. Target Price: Rs 920. Key drivers

Bank of Baroda (BOB) Banking. BUY Rating as per Large Cap 12 month investment period RETAIL EQUITY RESEARCH

Financial summary. Year

LIC Housing Finance BUY. Performance Highlights. CMP Target Price `532 `630. 3QFY2017 Result Update HFC. 3-Year Daily Price Chart

Capital Goods. 3QFY18E Results Preview. 10 Jan Sujit Jain

DCB Bank (DCB) 208. Healthy fundamentals priced in. Company Update. ICICI Securities Ltd Retail Equity Research. June 13, 2017

BUY. White cement steals the show JK CEMENT. Target Price: Rs 1,220. Other highlights

Buy Rating as per Mid Cap 12months investment period

Axis Bank Banking. HOLD Rating as per Large Cap 12 months investment period RETAIL EQUITY RESEARCH

HDFC Bank Banking. BUY Rating as per Large Ccap 12 month investment period RETAIL EQUITY RESEARCH

BUY. At inflection point NTPC. Target Price: Rs 197. Key highlights. Financial summary (Standalone) Y/E March FY16 FY17 FY18E FY19E.

BUY CMP (Rs.) 297 Target (Rs.) 385 Potential Upside 30%

Indostar Capital Finance

State Bank of India (SBI) Banking. BUY Rating as per Large Cap 12 month investment period RETAIL EQUITY RESEARCH

HOLD Rating as per Large Cap 12 month investment period

Ajanta Pharma Ltd. Rating: BUY. Pharmaceuticals. Ajanta Pharma STOCK IDEA

Ujjivan Financial Services Ltd Banking/Finance. BUY Rating as per Midcap 12 Months investment period RETAIL EQUITY RESEARCH

Equitas Holdings. Rating: Target price: ABV: Target CMP. Rating. Rs Rs. 226 BUY

LKP Bytes. Lakshmi Vilas Bank Outperformer. April 10, Q3 Financial Performance. Industry: Banking

(INR Crores) FY16 FY17 FY18 FY19E FY20E. Net interest income 15, , , , , Growth% -8% -2% 0% 26% 6%

LKP Bytes. Karnataka Bank. Outperformer. August 11, LKP Research. Industry: Banking

BUY. Well poised for strong growth RBL BANK. Target Price: Rs 650. Key highlights. Financial summary (Standalone) Y/E March FY17 FY18E FY19E FY20E

Bajaj Finance Limited (BFL) NBFC. BUY Rating as per Large Cap 12 months investment period RETAIL EQUITY RESEARCH

Ujjivan Financial Services Ltd Banking/Finance BUY RETAIL EQUITY RESEARCH

Healty cigarette-driven growth

Marico Kaya BUY RESULTS REVIEW 4QFY15 29 APR 2015

Recommendation BUY Snapshot CMP (01/08/2011) Rs. 85 Target Rs. 129

Bank of Baroda (BOB)

Jubilant FoodWorks NEUTRAL RESULTS REVIEW 4QFY17 30 MAY Highlights of the quarter

Agriculture. 4QFY18E Results Preview 13 APR Madhukar Ladha

Ujjivan Financial Services Ltd Banking/Finance. Buy RETAIL EQUITY RESEARCH

Dewan Housing Finance

Punjab National Bank

State Bank of India (SBI) Banking BUY RETAIL EQUITY RESEARCH

KEY FINANCIAL/VALUATIONS DEEPAK KUMAR BV

9,251 7,812 8, NIM

Punjab National Bank ACCUMULATE. Performance Highlights. CMP `1,115 Target Price `1,259. 3QFY2011 Result Update Banking.

BUY. Suprajit Engineering (SEL) Automobiles

Margin boost through non-core book

DCB Bank. Strong performance, valuation comforting

Jubilant FoodWorks BUY RESULTS REVIEW 1QFY18 18 JULY Highlights of the quarter

HOLD. Margins to improve from Q2 AMBUJA CEMENTS. Target Price: Rs 232. Other highlights

All round healthy performance

Punjab National Bank

DCB Bank. Accumulate. Healthy performance and comforting valuations Q4 FY16. Marre

BUY. Weak P&L performance, good b/s show POWER FINANCE CORP. Target Price: Rs 135. Financial summary (Standalone) Y/E March FY17 FY18E FY19E FY20E

I Direct. nstinct. November 27, 2017

Real Estate. 4QFY17E Results Preview. 13 Apr Parikshit D Kandpal

BUY STEEL STRIPS WHEELS LTD. Target Price: Rs Q4FY17: Heavier wheels outperform, strong growth triggers ahead FINANCIAL SUMMARY

IndusInd Bank (INDBA) 1717

Punjab National Bank

Karur Vysya Bank (KVB) KVB IN; KVB.BO

BHEL SELL RESULTS REVIEW 1QFY15 13 AUG CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188

South Indian Bank. Institutional Equities. 4QFY18 Result Update. Asset Quality Pain To Ease Hereafter BUY. 15 May 2018

Repco Home Finance REPCO IN

Transcription:

Karnataka Bank Bank - Private Date June 11, 2018 CMP (Rs.) 120 Target (Rs.) 163 Potential Upside 37% BSE Sensex 35484 NSE Nifty 10787 Scrip Code Bloomberg KBLIN Reuters KBNK.BO BSE Group A BSE Code 532652 NSE Symbol KTKBANK Market Data Market Cap. 3369 Equity Sh. Cap. (Rs) Cr) 283 52 Wk High/Low (Rs.) 179 / 107 Quarterly Avg Volume 318267 Face Value (Rs.) 10 Shareholding Pattern Short te Rating: BUY Incorporated in 1924, Karnataka Bank Limited (KBL) is one of the oldest private sector banks. It offers wide variety of products and services to around 9.7 million customers. KBL has bouquet of products in corporate and retail banking like housing loans, mortgages, vehicle loans, gold loans, educational loans etc. It has built network of 2,176 service outlets with 800 branches, 2 extension counters and 1,374 ATMs across India. KBL s Q4 FY18 performance was characterized by a better pre provisioning profit of Rs. 475 crores (44% y- o-y growth) on improving the net interest revenue traction which grew by 54% y-o-y to Rs. 541 crores and controlled operating expenses (Q4 FY18 cost to income ratio 43.14% as compared to 50.4% a year ago). As on FY18, total business of the bank (advances and deposits) is Rs. 1, 10,123 crores. Strong loan growth and borrower profile: Focus on retail and corporate sectors led to 28% loan growth in FY18 which was one of the challenging areas for the bank in the last couple of years. Corporate advances constitute 55% of total loan portfolio with balance in retail. Corporate borrowers with AAA and AA ratings constitute 13% and 8% respectively of the total gross advances. Going forward, management will focus on MSME, mid corporate and retail loans. Improved NIM and controlled operating expenses support operating profitability in FY18: NIM which improved by 39 bps y-o-y to 3.18% was mainly driven by the robust growth in NII (25% y-o-y to Rs. 1858 crores). Owing to the miniscule increase in operating expenditures of only 3% y-o-y, cost-to-income (C/I) ratio reduced to 48% in FY18 v/s 57% in FY17. As a result, pre provisioning profit for FY18 was up by 48% to Rs. 1473 crores (FY17: Rs. 995 crores).management has given guidance of NIM more than 3% in FY19. Asset Quality to stabilize: Asset quality of the bank has deteriorated sharply over the past years with GNPA increasing from 2.92% in FY14 to 4.91% in FY18. Fresh accretion to NPA was Rs. 654 crores as on FY18. Three power accounts have been identified under NPA and adequate provision for the same was made. Under NCLT cases, the bank had four accounts of Rs 317 crores and all these accounts were treated as NPA. Management commented that the bank has taken entire NPA stress in Q4 FY18 and expects slippages to minimize going forward with more focus on betterrated corporate and improving recovery management. Comparative Price Chart Marginal decline in CASA: CASA share has gone marginally down to 28% in FY18 v/s 29% in FY17. Retail term deposits were 71% of total deposits. With management focus on increasing the retail book, we expect CASA to improve going forward. Going forward, management aims to maintain CASA share of at least 30%. Expanding Reach: Over the last five years, the pace of branch additions of KBL has increased sharply from 600 in FY14 to 800 in FY18. The number of ATMs has almost been doubled from 700 in FY14 to 1374 in FY18. Bank is expanding its reach in northern region from 19 branches in FY14 to 24 branches in FY18. Management commented that Bank is planning to open 35 new branches in FY19 taking the total number of branches to 835. Arun Gopalan Research Analyst arungopalan@systematixgroup.in Brief Financials Outlook and Valuation: We are positive on KBL s business outlook on the back of following factors including 1) high likelihood of strong credit growth, 2) enhanced focus on retail, SME and mid corporate clients, 3) improving asset quality outlook and 4) improving operating efficiencies. Therefore, we recommend BUY recommendation on the stock with a target price of Rs. 163 based on 0.7x FY20E adjusted book value, an upside of 37%. Financials NII PPP PAT EPS (Rs) FY17 1490.0 995.0 451.0 16.0 178.0 0.7 4.2 2.6 2.8 13.3 FY18 1858.0 1473.0 325.0 11.0 186.0 0.6 4.9 3.0 3.2 12.0 FY19E 2144.0 1710.0 546.0 19.0 206.0 0.6 4.6 2.7 3.2 11.1 FY20E 2596.0 2107.0 744.0 26.0 233.0 0.5 4.3 2.4 3.2 10.4 ABVPS (Rs.) P/ABV (x) GNPA NNPA NIM CAR

Advances and Growth in Advances CASA and CASA Ratio NII and NIM% Ratios Gross NPA and Gross NPA % Net NPA and Net NPA %

QUARTERLY FINANCIALS Healthy Net Interest Income traction, supported by improving advances growth and sustained margins Controlled expenses resulted into lower operating expenses Income Statement (Rs. in crores) Interest Income 1331 1318 1332 1443 Interest Expense 906 878 881 902 Net Interest Income 425 440 451 542 n-interest Income 217 248 195 295 Net Revenue 642 688 646 836 Employees Expenses 137 124 121 142 Other Operating Expenses 195 198 203 219 Profit Before Provisions 310 366 322 475 Provisions 199 226 196 542 Profit Before tax 111 140 125-67 Tax -23 47 38-77 Net Profit 134 93 87 11 EPS (Rs.) 5 3 3 0.4 Asset Quality Gross NPA (Rs in crores) 1691 1716 1784 2376 Gross NPA 4.3 4.1 4.0 4.9 Net NPA (Rs in crores) 1230 1247 1263 1401 Net NPA 3.2 3.0 2.9 3.0 Interesting part: NIM of Q4 FY18 is more than FY18 Financial Ratios Net Interest Margin (NIM) 2.6 3.0 3.1 3.5 Yield on Advances 10.2 10.2 10.1 9.8 Cost of Deposits 5.5 5.3 5.3 5.2 RoA 0.8 0.6 0.5 0.1 RoE 10.3 8.7 6.5 0.8 CRAR 13.0 12.5 12.3 12.0 CASA 28.9 28.6 28.2 28.0

YEARLY FINANCIALS Income Statement (Rs. in crores) Interest Income 4992 5185 5424 5727 6206 Interest Expense 3689 3695 3566 3583 3610 Net Interest Income 1303 1490 1858 2144 2596 n-interest Income 543 809 954 1049 1154 Net Revenue 1846 2299 2812 3194 3750 Employees Expenses 443 601 525 588 659 Other Operating Expenses 548 703 814 895 985 Profit Before Provisions 855 995 1473 1710 2107 Provisions 327 528 1163 982 1115 Profit Before Tax 528 467 310 728 992 Tax 113 16-15 182 248 Net Profit 415 451 325 546 744 EPS (Rs.) 22 16 11 19 26 DPS (Rs.) 1.1 0.3 0.3 0.3 0.3 Balance sheet (Rs. in crores) Capital 188 283 283 283 283 Reserves and Surplus 3502 4860 5128 5674 6418 Borrowings 50488 56733 62871 72827 84527 Other Liabilities and Provisions 2322 2163 2092 2197 2306 Total Liabilities 56500 64039 70374 80981 93535 Advances 33902 36916 47252 56702 68043 Investments 16257 20220 15444 16216 17027 Fixed Assets 306 721 762 800 840 Other Assets 6035 6182 6916 7262 7625 Total Assets 56500 64039 70374 80981 93535 Key Assumptions and Ratios Growth ratios Advances 7.0 8.9 28.0 20.0 20.0 Net Interest Income 11.6 14.4 24.7 15.4 21.1 Profit After Tax -8.0 8.7-27.9 68.1 36.2 Margin ratios Net Interest Margin (NIM) 2.4 2.8 3.2 3.2 3.2 Yield of Funds 11.6 10.8 9.8 9.9 9.9 Cost of Funds 7.5 6.7 6.1 6.2 6.3 Valuation ratios Book Value per Share (Rs.) 196 182 191 211 237 Adjusted Book Value per Share (Rs.) 192 178 186 206 233 P/ BV 0.6 0.6 0.5 P/ ABV 0.6 0.6 0.5 Return ratios RoA 0.8 0.7 0.5 0.7 0.9 RoE 11.7 10.2 6.2 9.6 11.8 Other ratios Cost to Income Ratio 53.7 56.7 47.6 46.4 43.8 CRAR 12.0 13.3 12.0 11.1 10.4 Gross NPA 3.4 4.2 4.9 4.6 4.3 Net NPA 2.4 2.6 3.0 2.7 2.4

DISCLOSURES/ APPENDIX I. ANALYST CERTIFICATION I, Arun Gopalan, hereby certify (1) that the views expressed in this research report accurately reflect my personal views about any or all o f the subject securities or issuers referred to in this research report, (2) part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by Systematix Shares and Stocks (India) Limited or its Group/associates companies. (3) has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations. Disclosure of Interest Statement Response Analyst holding in the stock Served as an officer, director or employee II. ISSUER SPECIFIC REGULATORY DISCLOSURES, UNLESS SPECIFICALLY MENTIONED IN POINT NO. 9 BELOW: 1. The Research Analyst(s), Systematix Shares and Stocks (India) Limited, Associate of Analyst or his relative does not have any financial interest in the company(ies) covered in this report. 2. The Research Analyst, Systematix Shares and Stocks (India) Limited or its associates or relatives of the Research Analyst affiliates collectively do not hold more than 1% of the securities of the company (ies) covered in this report as of the end of the month immediately preceding the distribution of the research report. 3. The Research Analyst, his associate, his relative and Systematix Shares and Stocks (India) Limited do not have any other material conflict of interest at the time of publication of this research report. 4. The Research Analyst, Systematix Shares and Stocks (India) Limited and its associates have not received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in this report, in the past twelve months. 5. The Research Analyst, Systematix Shares and Stocks (India) Limited or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for the company (ies) covered in this report. 6. Systematix Shares and Stocks (India) Limited or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party, in connection with the research report. 7. The Research Analyst has not served as an Officer, Director or employee of the company (ies) covered in the Research report. 8. The Research Analyst and Systematix Shares and Stocks (India) Limited has not been engaged in market making activity for the company(ies) covered in the Research report. 9. Details Systematix Shares and Stocks (India) Limited, Research Analyst and its associates pertaining to the companies covered in the Research report: Sr. Particulars Yes /.. 1 Whether compensation has been received from the company(ies) covered in the Research report in the past 12 months for investment banking transaction by Systematix Shares and Stocks (India) Limited 2 Whether Research Analyst, Systematix Shares and Stocks (India) Limited or its associates or relatives of the Research Analyst affiliates collectively hold more than 1% of the company(ies) covered in the Research report 3 Whether compensation has been received by Systematix Shares and Stocks (India) Limited or its associates from the company(ies) covered in the Research report 4 Systematix Shares and Stocks (India) Limited or its affiliates have managed or co-managed in the previous twelve months a private or public offering of securities for the company(ies) covered in the Research report 5 Research Analyst, his associate, Systematix Shares and Stocks (India) Limited or its associates have received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in the Research report, in the last twelve month 10. There are no material disciplinary action that been taken by any regulatory authority impacting equity research analysis activities. 11. Systematix Shares and Stocks (India) Limited is in a process of seeking registration under SEBI (Research Analyst) Regulations, 2014. EXPLANATION TO RATINGS: BUY: TP>15%; ACCUMULATE: 5%<TP<15%; HOLD: -5%<TP<5%; REDUCE: -15%<TP<-5%; SELL: TP<-15% III. DISCLAIMER The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been i ndependently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness. This document is for information purposes only. This report is based on information that we consider reliable, but we do not represent that it is accurate or complete, and one should exercise due caution while acting on it. Descriptions of any company or companies or their securities mentioned herein are not complete and this document is not, and should not be constr ued as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus an y other information contained in the report, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to Systematix Shares and Stocks (India) Limited or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently send or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United State (to U.S.Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication, redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the Report is intended solely for the recipient and may not be further distributed by the recipient to any third party. Systematix Shares and Stocks (India) Limited generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, Systematix Shares and Stocks (India) Limited generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board me mber of any companies that the analysts cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clie nts that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by Systematix Shares and Stocks (India) Limited however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of Systematix Shares and Stocks (India) Limited may provide important inputs to its affiliated company(ies). Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY. Systematix Shares and Stocks (India) Limited, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of th is report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Systematix Shares and Stocks (India) Limited and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those o f the analyst and the Company may or may not subscribe to the views expressed therein. Systematix Shares and Stocks (India) Limited, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall Systematix Shares and Stocks (India) Limited, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The Company accepts no liability whatsoever for the actions of third parties. The Report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Report refers to website material of the Company, the Company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the Company shall be at your own risk and the Company shall have no liability arising out of, or in connection with, any such referenced website Systematix Shares and Stocks (India) Limited shall not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall the Systematix Shares and Stocks (India) Limited be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data pre sented by Systematix Shares and Stocks (India) Limited through this presentation. Neither Systematix Shares and Stocks (India) Limited, nor any of its other group companies or associates, shall be responsible for any decisions taken on the basis of this report. Investors are advised to consult their Investment and Tax consultants before taking any investment decisions based on this report. Systematix Shares and Stocks (India) Limited. CIN : U65993MH1995PLC268414 BSE SEBI Reg..: INZ000171134 (Member Code: 182) NSE SEBI Reg..: INZ000171134 (Member Code: 11327) MSEI SEBI Reg..: INZ000171134 (Member Code: 17560) Depository Participant SEBI Reg..: IN-DP-CDSL-246-2004 (DP Id: 34600) PMS SEBI Reg..: INP000002692 Research Analyst SEBI Reg..: INH200000840 Investment Advisor SEBI Reg.. INA000010414 AMFI : ARN - 64917 Registered and Corporate Office Address: The Capital, A-wing,. 603 606, 6th Floor, Plot. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051